Skip to main content
. 2016 Jul 18;11:3239–3253. doi: 10.2147/IJN.S108143

Figure 6.

Figure 6

The in vivo antitumor efficacy of different formulations of ACGs against 4T1 tumor-bearing mice after intravenous administration.

Notes: (A) The growth of tumor volume over time. (B) Relative body weight change with time. All data represent the mean ± SD (n=10). **P<0.01, ***P<0.001.

Abbreviations: ACGs, annonaceous acetogenins; NSps, nanosuspensions; HCPT, hydroxycamptothecin; iv, intravenous; ig, intragastric.